Multiple sclerosis is one of the most actively researched conditions in stem cell medicine, with two fundamentally different approaches: hematopoietic stem cell transplant (HSCT) and mesenchymal stem cell (MSC) therapy. The evidence levels, mechanisms, risks, and costs differ dramatically between them. This guide separates what is established from what is experimental.
🏛 Regulatory Status
HSCT for MS has Level 1–2 evidence for aggressive relapsing-remitting MS (RRMS) and has shown superiority to disease-modifying therapies in the MIST trial. MSC infusion for MS has Level 2–3 evidence with promising but inconsistent results. These are different treatments with different risk profiles.
HSCT vs. MSC: Two Different Approaches
| Factor | HSCT | MSC Therapy |
|---|---|---|
| Mechanism | Immune system reset via ablation + reconstitution | Anti-inflammatory + immunomodulatory signaling |
| Evidence level | Level 1–2 (RCTs exist, including MIST trial) | Level 2–3 (smaller controlled studies, case series) |
| Best candidates | Aggressive RRMS, young, early disease, high inflammatory activity | RRMS or SPMS with ongoing inflammation, less aggressive disease |
| Risk level | High (chemotherapy-level immune ablation) | Low (IV infusion, minimal procedure risk) |
| Cost in US | $100,000–$300,000 | $5,000–$25,000 (not covered by insurance) |
| Cost in Colombia | $30,000–$60,000 (HSCT) | $5,000–$15,000 (MSC infusion) |
| Recovery time | Months (immune reconstitution) | Days (outpatient procedure) |
| Retreatment | Usually once | May repeat every 6–12 months |
What the Evidence Actually Shows for MSC Therapy in MS
Published studies on MSC infusion for MS show reduced relapse rates in some patients, improvements in EDSS disability scores in a subset of responders, MRI evidence of reduced new lesion formation, and a favorable safety profile. However, results are inconsistent across studies, optimal dosing and frequency are not established, and long-term outcomes beyond 2 to 3 years are limited. Patients with high inflammatory activity and early-stage disease appear to respond better than those with progressive, low-inflammation MS.
For honest assessment of whether stem cell therapy is appropriate for your MS subtype, connect through colombiastemcelltreatment.com or the broader network at colombiamedical.co.
Ready to Explore Your Options?
Connect with us for an honest assessment of whether stem cell therapy is appropriate for your condition.
💬 Chat on WhatsApp